StemCells Completes SCS Acquisition | GenomeWeb

NEW YORK (GenomeWeb News) – StemCells today announced that it has completed its acquisition of UK-based Stem Cell Sciences for 2.65 million shares of its common stock and $700,000 in cash.

Based on the Tuesday closing price of StemCells' stock ($1.67), the deal is valued at around $4.4 million, lower than the $4.8 million estimated when the deal was signed in early March. SCS' shareholders overwhelmingly approved the deal last week at an extraordinary general meeting.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.